sábado, 14 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Via News Knowledge File

D-Wave Quantum Inc.

organization80% conf.·synced Aug 13, 2026

Quantum computing company specializing in annealing quantum computers and Quantum Compute as a Service

54
sourced metrics
204
relationships
20
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Share
179.30price_to_sales_ratio
May 26, 2026source
Cash
588USD
May 19, 2026source
Backlog
33.4USD
May 19, 2026source
Gross Margin Gaap
55.8percent
Jan 22, 2026⚠ sources conflictsource
Gross Margin Non Gaap
67.2percent
Jan 22, 2026⚠ sources conflictsource
Lincoln Park Equity Line Remaining
49.9million_USD
Jan 22, 2026source
Bookings
7.4million_USD
Jan 22, 2026⚠ sources conflictsource
Adjusted Ebitda Loss
13.8million_USD
Jan 22, 2026⚠ sources conflictsource
Atm Program Remaining
79.1million_USD
Jan 22, 2026source
Eps
-0.51USD
Jan 22, 2026⚠ sources conflictsource
Total Customers
132customers
Jan 22, 2026⚠ sources conflictsource
Commercial Customers
76customers
Jan 22, 2026⚠ sources conflictsource
Commercial Revenue Decrease
0.2million_USD
Jan 22, 2026source
Forbes Global 2000 Customers
27customers
Jan 22, 2026⚠ sources conflictsource
Research Revenue Increase
0.6million_USD
Jan 22, 2026source
Qcaas Revenue
5.1million_USD
Jan 22, 2026⚠ sources conflictsource
Professional Services Revenue
0.3million_USD
Jan 22, 2026⚠ sources conflictsource
Patent Count
240patents
Jan 22, 2026⚠ sources conflictsource

Stated objectives

Q1 2025 revenue expected to exceed $10M

source
target: >10M USD by 2025-03-31 00:00:00stated

Commercial rollout of Advantage 2 system planned for 2025

source
by 2025-12-31 00:00:00stated

Reach profitability as first pure play quantum company

source
target: positive net income stated

Complete testing of Advantage3 prototype chip

source
by 2025-12-31 00:00:00stated

Demonstrate first gate model fluxonium qubit system with scalable cryogenic control

source
by 2026-12-31 00:00:00stated

Deploy scaled error-corrected gate model quantum system

source
stated

Scale Advantage3 to 100,000 qubits with multi-chip processor fabric

source
target: 100000 qubits stated

Deploy Advantage2 system in Lombardy, Italy for Q-Alliance

source
by 2026-12-31 00:00:00stated

Achieve path to profitability with commercial QCaaS and system sales model

source
stated

Achieve sustained profitability as first independent public quantum company

source
target: sustained profitability stated

Relationship graph · 204 connections

Competes with
63
Customer of
40
Developed by
23
Supplies to
11
listed on
10
Covered by
10
Employs
10
contracted by
5
headquartered in
Palo Alto

Via News coverage

Palantir sube en las apuestas de los analistas mientras Wall Street enfría al sector de defensa: lo que sí está verificado, y lo que no
October 19, 2026
La fiebre de la infraestructura de IA: Micron duplica su inversión mientras los analistas avisan de valoraciones al límite
October 9, 2026
El auge de la infraestructura de IA, medido en las cuentas de Micron: el gasto en inversión se duplicó en dos años mientras el consumo y la tecnología especulativa flaquean
October 1, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com